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BLETTER TO THE EDITOR
irolimus-Related Toxicity in Stem Cell
ransplantation
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sWe read with interest the recently published arti-
le by Johnston et al., [1] which evaluated the efﬁcacy
nd safety of sirolimus in combination with cal-
ineurin inhibitors and steroids for the treatment of
hronic graft-versus-host disease (cGVHD). The
tudy indicates that sirolimus in conjunction with cal-
ineurin inhibitors has activity in the treatment of
GVHD, although 37% of the patients developed
evere toxicity (grade 3-4; National Cancer Institute
ommon Toxicity Criteria).
Here we report our retrospective analysis on the
se of sirolimus in patients undergoing allogeneic he-
atopoietic stem cell transplantation (HSCT). Be-
ween February 2003 and December 2004, 15 patients
eceiving an allogeneic HSCT from HLA-identical
iblings (n  10), partially matched related donors
n  2), or matched unrelated donors (n  3) were
iven sirolimus. The immunosuppressant was intro-
uced because of refractory cGVHD (n  2) or cal-
ineurin inhibitor–related toxicity (n  13); this in-
luded renal insufﬁciency in all cases. Two patients
ad additional toxicity, including hepatic toxicity (n 
) and thrombotic microangiopathy (n  1). In pa-
ients with a history of calcineurin inhibitor toxicity,
irolimus was introduced as a GVHD prophylactic
egimen (n  9) or GVHD treatment (n  4) in an
ttempt to taper off the calcineurin inhibitor. Siroli-
us was initiated at 2 mg/d in 5 patients and 4 mg/d
n 6 patients. This was targeted to maintain sirolimus
rough concentrations of 5 to 15 mg/dL; 4 patients
eceived sirolimus orally at a loading dose of 6 mg,
ollowed by a maintenance dose of 2 mg/d. The me-
ian time to start sirolimus was 49 days (range, 10-
760 days) after transplantation (Table 1). Patients
ere treated with sirolimus in addition to steroids (n
2), calcineurin inhibitors and steroids (n  3),
ycophenolate mofetil (MMF; n  2), MMF and
alcineurin inhibitor (n  4), and MMF and steroids
n  3); 1 patient received sirolimus alone. Throm-
ocytopenia (platelets 50 000/L) was the most
ommon adverse event, occurring in 9 (60%) patients.
n 3 cases, thrombocytopenia was associated with the
resence of platelet autoantibodies. In 5 patients, the
umber of platelets normalized after either removal of c
B & M Tr reduction in the dose of sirolimus. Neutropenia
absolute neutrophil count 1000/L) was noted in 6
40%) patients. Three patients had complete resolu-
ion of neutropenia after the administration of gran-
locyte colony-stimulating factor; in 2 patients, the
bsolute neutrophil count normalized with no dose
odiﬁcation of sirolimus. One patient had persistent
eutropenia even after discontinuation of sirolimus
nd required a second marrow graft. Renal insufﬁ-
iency occurred in 5 (33%) patients.
Because 13 of 15 patients had a history of neph-
otoxicity, for the purposes of this study, sirolimus-
elated renal toxicity was deﬁned as an increase of
reatinine levels 65% times baseline (ie, the value of
reatinine before the ﬁrst dose of sirolimus) with cre-
tinine levels 2.0 mg/dL. The median time to de-
elop renal toxicity was 30 days (range, 4-73 days)
fter the introduction of sirolimus. In 3 of the 5
atients, there was a concomitant administration of
alcineurin inhibitor. Hypertriglyceridemia (triglycer-
des 600 mg/dL) was noted in 4 (27%) patients,
hereas hemolytic uremic syndrome occurred in 1
atient (7%). Two (13%) patients did not have evi-
ence of sirolimus-related toxicity. The correlation
etween sirolimus blood levels and the occurrence of
dverse events has been analyzed in detail. Overall,
upratherapeutic (15 ng/mL) sirolimus levels were
oted in 45% of measured values, and very high levels
25 ng/mL) were noted in 20% of measured values.
ll patients who developed nephrotoxicity, 3 of 6
atients who developed neutropenia, and 6 of 9 pa-
ients who developed thrombocytopenia had high
irolimus levels (25 ng/mL) at the time of the toxic
vent. Of note, 5 patients developed hematologic tox-
city despite normal sirolimus levels (Table 1). For
atients with high sirolimus levels, the median oral
ose of sirolimus at the time of testing was 2 mg/d
range, 1-4 mg/d). Nine (60%) patients discontinued
irolimus after a median of 43 days (range, 23-139
ays) because of nephrotoxicity (n  4), cytopenia
n  2), relapse (n  2), or resolution of cGVHD
n  1). Two of the 4 patients who discontinued
irolimus because of nephrotoxicity were receiving a
oncomitant calcineurin inhibitor. Three of the 6 pa-
647
Table 1. Drug Levels and Adverse Events Observed in Patients Receiving Sirolimus
Patient
No.
Oral Dose of
Sirolimus
(mg)*
Time to Start
Sirolimus from
HSCT (d)
Sirolimus
Level
(ng/mL)† Toxicity Laboratory Value
Concomitant
IST Outcome
100A 2 5760 25 Nephrotoxicity Creatinine (mg/dL): 2.7 CSA
Normalized, no sirolimus dose
modification
1519 2 10 29 Nephrotoxicity Creatinine (mg/dL): 4.4 —
Normalized, no sirolimus dose
modification
241 2 27 32 Nephrotoxicity Creatinine (mg/dL): 2.0 —
Normalized after withdrawal of
sirolimus
220 3 220 25 Nephrotoxicity Creatinine (mg/dL): 2.0 Tacrolimus
Normalized after dose
reduction of sirolimus
218 2 26 26 Nephrotoxicity Creatinine (mg/dL): 2.6 CSA
Normalized after dose
reduction of sirolimus
233 4 284 42 Neutropenia ANC/L: 500 MMF Normalized after G-CSF
1520 2 31 40 Neutropenia ANC/L: 250 —
Persistent poor marrow
function after G-CSF
administration
241 2 27 50 Neutropenia ANC/L: 925 — Normalized without G-CSF
243 4 99 NR Neutropenia ANC/L: 580 — Normalized after G-CSF
1051 4 37 NR Neutropenia ANC/L: 590 MMF Normalized without G-CSF
1044 8 49 NR Neutropenia ANC/L: 550 MMF Normalized after G-CSF
243 4 99 NR Thrombocytopenia Platelets/L: 18 000 Tacrolimus
Normalized after withdrawal of
sirolimus
220 3 220 25 Thrombocytopenia Platelets/L: 41 000 Tacrolimus Persistent thrombocytopenia
218 2 26 20 Thrombocytopenia Platelets/L: 27 000 CSA
Normalized after dose
reduction of sirolimus
233 4 284 42 Thrombocytopenia Platelets/L: 50 000 MMF
Normalized after withdrawal of
sirolimus
250 3 14 50 Thrombocytopenia Platelets/L: 50 000 MMF
Normalized after withdrawal of
sirolimus
232 1 86 31 Thrombocytopenia Platelets/L: 29 000 —
Normalized after withdrawal of
sirolimus
1520 2 31 40 Thrombocytopenia Platelets/L: 16 000 —
Increase after withdrawal of
sirolimus
1519 2 10 NR Thrombocytopenia Platelets/L: 29 000 — Persistent thrombocytopenia
241 2 27 50 Thrombocytopenia Platelets/L: 14 000 —
Normalized after withdrawal of
sirolimus
HSCT indicates hematopoietic stem cell transplantation; IST, immunosuppressive treatment; NR, normal range; ANC, absolute neutrophil count; CSA, cyclosporine; MMF, mycophenolate mofetil;
G-CSF, granulocyte colony-stimulating factor.
*Dose of sirolimus administered at the time of corresponding trough level measurement.
†The levels are expressed as the maximum sirolimus measurement during the 7-day period preceding the toxic event.
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Letter to the Editor
Bients who received sirolimus as treatment of cGVHD
howed objective responses (2 complete responses and
partial response), and 5 of the 9 patients who re-
eived sirolimus as GVHD prophylaxis developed ei-
her acute or chronic GVHD; however, given the
mall sample size and the retrospective nature of the
tudy, these ﬁndings should be interpreted with cau-
ion.
The incidence of renal toxicity and hemolytic uremic
yndrome observed in our series was comparable to that
eported by Johnston et al. [1] (40% versus 50%, respec-
ively). This observation conﬁrms that the rate of siroli-
us-related nephrotoxicity after allogeneic HSCT is
uch higher than the rate reported in the renal trans-
lant patient population [2]. However, it should be un-
erscored that 13 of 15 patients included in our study
eceived sirolimus because of nephrotoxicity due to prior
xposure to a calcineurin inhibitor, and this fact might
ave promoted the nephrotoxic effects of sirolimus. Sur-
risingly, in our experience, the rates of both neutrope-
ia and thrombocytopenia were signiﬁcantly high: over-
ll, 11 patients (73%) developed cytopenias (5 with
hrombocytopenia, 2 with neutropenia, and 4 with
hrombocytopenia and neutropenia). Even if we exclude
rom the analysis patients without a clear correlation
etween sirolimus administration and cytopenias (ie, pa-
ients with autoimmune thrombocytopenia and patients
ho did not respond to sirolimus dose modiﬁcation or
ithdrawal), 33% (5/15) of the patients included in our
tudy developed hematologic toxicity. In this respect, the
oncomitant therapy with MMF in 4 patients and the
harmacokinetic interaction between the 2 drugs [3]
ay explain, at least partially, the exaggerated myelosup-
ressive side effects. High rates of toxic levels of siroli-
us have been observed in our study. Many factors,
ncluding hepatic dysfunction, intestinal diseases, and the
dministration of sirolimus, along with other drugs (ﬂu-
B & M Tonazole or itraconazole), may be relevant. Of concern
as the lack of correlation between sirolimus doses and
rough levels, although this ﬁnding has been reported
reviously by others.[4] It should also be emphasized
hat 36% of the patients who experienced hematologic
oxicity had normal sirolimus trough concentrations.
In conclusion, our results strengthen the observa-
ions of Johnston and associates and suggest that cli-
icians must remain vigilant to the potential toxic
omplications of sirolimus in the stem cell transplant
etting. Additional studies to investigate pharmaco-
ogic interactions and dose optimization seem war-
anted.
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